Trials / Unknown

UnknownNCT06236295

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Status: Unknown
Phase: Phase 2
Study type: Interventional
Enrollment: 303 (actual)

Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. · Industry
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

This is a multicenter, single-arm, long-term safety and tolerability trial. A total of 300 subjects with chronic kidney disease on hemodialysis are planned to be enrolled.

Conditions

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

Interventions

Type	Name	Description
DRUG	SHR6508	SHR6508 will be administered to all the eligible subjects

Timeline

Start date: 2024-02-20
Primary completion: 2025-12-01
Completion: 2025-12-01
First posted: 2024-02-01
Last updated: 2024-07-10

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06236295. Inclusion in this directory is not an endorsement.